Danaher Corp (NYSE:DHR) on Tuesday reported first-quarter 2026 sales of $5.95 billion, up 3.5% year-over-year, but under the consensus of $5.99 billion. Core revenue increased 0.5% year-over-year.
The life science giant reported adjusted earnings of $2.06 per share, beating the consensus of $1.94. Operating cash flow was $1.3 billion, and adjusted free cash flow was $1.1 billion.
Danaher’s first-quarter adjusted operating profit margin of 30.2% exceeded expectations of approximately 28.5%.
• Danaher shares are experiencing downward pressure. Why are DHR shares declining?
Bioprocessing Lead Segment Danaher Growth
Biotechnology sales increased to $1.797 billion compared to $1.61 billion a year ago, with core growth of 7%.
Bioprocessing sales jumped in high single digits, led by consumables. Equipment order growth was over 30% in the first quarter.
Sales in the Life Sciences segment reached $1.74 billion, a slight jump from $1.68 billion a year ago. …